002788SZSE

Independent Director's 2025 Annual Work Report (Wu Junlong)

Luyan Pharmaceutical Co., Ltd.··4p

✨ AI Summary

This report details the independent director's 2025 work, focusing on corporate governance and financial oversight. The director attended all 4 board meetings and 1 shareholder meeting, actively participating in discussions and providing guidance. Key activities included reviewing financial reports, ensuring compliance, enhancing internal controls, and protecting minority shareholder rights. The director also conducted field investigations to assess company operations and regulatory adherence, aiming for sustainable development.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· azure_openaiSign In to Upgrade

Dear shareholders and representatives:

This report is based on the requirements of the Company Law and the Articles of Association of the Company. It aims to provide an overview of the independent director's work in 2025.

2025 Annual Work Situation

In 2025, the independent director actively participated in board meetings and provided guidance on corporate governance. The details of the meetings are as follows:

Meeting TypeNumber of MeetingsParticipation CountVoting Situation (For)Voting Situation (Against)
Board Meetings4400

2025 Annual Shareholder Meeting Situation

The shareholder meeting situation is as follows:

Meeting TypeNumber of MeetingsParticipation CountVoting Situation (For)Voting Situation (Against)
Shareholder Meetings1100

The report includes the agenda of the board meetings, the resolutions passed, and the independent director's opinions on various matters.

3. Key Points of Attention in Financial Matters

(1) Regarding the financial situation during the reporting period, the company has maintained a stable financial condition. The board has reviewed the financial reports and ensured compliance with relevant regulations.

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.

Notes & Comments

Sign in to leave a comment or private note.

Loading…